Navigation Links
Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008
Date:10/15/2008

mprove patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.


'/>"/>
SOURCE Masimo Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
2. Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices
3. Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference
4. Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference
5. Masimo Reports First Quarter 2008 Financial Results
6. Atom Medical Adopts Masimo Rainbow SET Technology
7. Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide
8. Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference
9. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
10. Masimo Announces Continuous Noninvasive Total Hemoglobin
11. Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... --  Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, today reported 2014 full year ... objectives, and financial guidance.  Synageva,s management team will ... EST to review the financial results and provide ... call by telephone, please dial (877) 445-4603 for ...
(Date:2/26/2015)... The Movement for Indefinite Life Extension (MILE) ... technologies and awareness. The event is taking place from ... 21st 2015, in a live Google Hangout broadcast from ... of MILE, says, “Our lives are in our hands, ... Indefinite Life Extension is raising awareness about bio-sciences and ...
(Date:2/26/2015)... 26, 2015 BioEnterprise today announced that ... more than $2 billion in growth funding during the ... investors, strategic sources, state – including the Ohio Third ... $2 billion has been raised in the past five ... heels of the BioEnterprise Midwest Healthcare Growth Capital ...
(Date:2/26/2015)... RURO, Inc., a leading LIMS, RFID and sample ... latest update to the bestselling commercial-off-the-shelf sample management system. ... and easy method to gain better control of sample ... has enhanced the system’s support for those customers who ... records. , "FreezerPro has become the go-to system ...
Breaking Biology Technology:Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4RURO Releases FreezerPro® version 6.2 2
... , PALO ALTO, Calif., June 25 Varian ... announced it has acquired the assets of Houston-based IKOEmed ... planning of radiotherapy and radiosurgery treatments. The acquisition enables ... tool to automate and accelerate the most time-consuming portion ...
... of Phase II Trial for IPLEX(TM) in MMD Patients ... Va. , June 25 Insmed Inc. (Nasdaq: ... results from its exploratory U.S. Phase II clinical trial ... dystrophy ("MMD"). The randomized, double-blind, placebo-controlled Phase II ...
... ... markets. The global Nanomedicine market continues to register robust growth largely fueled by unique ... rise in funding across the globe, and increased hype around nanotechnology. , ... San Jose, CA (PRWEB) June ...
Cached Biology Technology:Varian Medical Systems Acquires Assets of IKOEmed and IKOEtech; Acquisition to Add Software for Accelerating Radiotherapy Treatment Planning 2Varian Medical Systems Acquires Assets of IKOEmed and IKOEtech; Acquisition to Add Software for Accelerating Radiotherapy Treatment Planning 3Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy 2Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy 3Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy 4World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 2World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 3
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... corporate website ( http://www.nxt-id.com/ ) as part of its ... wallet. The Company launched its new consumer website for ... Pereira , CEO of NXT-ID said, "Our new corporate ...
(Date:2/5/2015)... JOLLA, Calif. , Jan. 30, 2015  It ... the great power and potential for genomic science as ... aid in disease prevention and treatment.  I was honored ... potential new, government-funded precision medicine program. ... advancing the science of genomics—from the first sequenced genome ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... Lung cancer is the most commonly diagnosed cancer in the ... but scientists are working on ways to improve their understanding ... gather in San Diego at the San Diego Marriott Marquis ... Conference on Molecular Origins of Lung Cancer: Biology, Therapy and ...
... - Newly published research by scientists at Oregon Health ... early embryonic stem cells develop and take part in ... place at OHSU,s Oregon National Primate Research Center, has ... monkeys -- monkeys developed from stem cells taken from ...
... UCLA researchers have identified how a component of an ... the plant Hovenia, counteracts acute alcohol intoxication and withdrawal ... the action of alcohol on the brain and neurons ... side effects, in an early study with rats. Specifically, ...
Cached Biology News:Lung cancer conference to focus on new diagnostic techniques, potential treatments 2OHSU research produces the world's first primate chimeric offspring 2
... at the 9, 10, 12, and 13 positions. ... standard for the quantification of 13(S)-HODE by GC- ... of linoleic acid with plant and mammalian lipoxygenases. ... of tumor cells to the endothelium at concentrations ...
... Proteomics Analyzer Mass Standards Kit includes reagents ... function, optimize instrument parameters, and calibrate the ... kit is designed for use with the ... spectrometry system. Standards in the kit require ...
...
...
Biology Products: